Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14858
Abstract: The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC… read more here.
Keywords: therapy egfr; targeted therapy; egfr mutation; mutation ... See more keywords